Last Updated : Thursday, July 11, 2019 12:45:54

Torrent Pharma inks diabetic drug marketing pact with Glenmark Pharma

AHMEDABAD | MUMBAI | RAJKOT –  In a press release submitted to the Indian Bourses by Glenmark Pharma it said that, Ahmedabad headquartered Torrent Pharmaceuticals and Glenmark Pharmaceuticals Ltd have inked agreement for co-marketing of diabetic treatment drug Remogliflozin Etabonate in India.

The press release submitted to the Indian Exchanges on Thursday read that, Glenmark Pharmaceuticals Ltd. (Glenmark), and Torrent Pharmaceuticals Limited (Torrent) today announced that they have entered into a non‐exclusive sub‐licensing agreement to co‐market sodium glucose co‐transporter‐2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India.


Under the terms of the agreement, Glenmark will receive an upfront payment, license fees and royalties for the non‐exclusive sub‐license rights from Torrent.

Glenmark will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark ‘Zucator’ in India.

In April 2019, Glenmark received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase‐3 clinical trials in which Remogliflozin demonstrated good efficacy and safety profile in a head‐to‐head comparison against Dapagliflozin.

Subsequently, Glenmark launched Remogliflozin indicated in the treatment of Type 2 Diabetes Mellitus in adults under the brand names ‘Remo’ and ‘Remozen’ while Torrent will commercialize Remogliflozin under the brand name ‘Zucator’.

Moreover, Remogliflozin is available at a breakthrough price that is significantly lower and cost effective over other SGLT‐2 inhibitors available in the country.

Infact, Remogliflozin is the only SGLT2 inhibitor to be manufactured in India from active pharmaceutical ingredient (API) to formulation.


Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a new group of oral medications used for treatment of type 2 diabetes in patients.

The drug functions in helping the kidneys to lower blood glucose levels.

SGLT2 inhibitors have been approved for use as a treatment for diabetes since year 2013.

SGLT2 drugs are taken once a day with or without food.


Sujesh Vasudevan, President, India Formulations, Middle East & Africa at Glenmark Pharmaceuticals said,

“We are pleased to partner and work closely with Torrent to provide access to innovative solutions for efficient diabetes management in India. The burden of diabetesin India is growing at an alarming rate and through this collaboration, we aim to improve access to the latest, novel and globally‐researched SGLT2 inhibitor by providing an effective, high quality and world‐class treatment option to patients in India. This partnership will also lay the foundation for a long term collaboration with Torrent for Remogliflozin in terms of its additional line extensions and further clinical development.”

Dhruv Gulati, Executive Director (India & ROW), Torrent Pharma, said,

“We are pleased to collaborate with Glenmark for the novel anti‐diabetic drug Remogliflozin. The drug will augment the Type 2 Diabetes Mellitus treatment armamentarium in the country and this partnership will be an important step towards enhancing access to the growing needs of diabetic patients.”

For more details, please click the link, given here :


FacebookGoogle+LinkedinTwitterYouTube, Blogspot, Telegram, Instagram 


Do NOT follow this link or you will be banned from the site!